Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human bladder cancer

Cancer Immunity

Volumn 7, Issue , 2007, Pages

  Liakou, Chrysoula I ^a   Narayanan, Sowmita ^a   Tang, Derek Ng ^a   Logothetis, Christopher J ^a   Sharma, Padmanee ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Bladder cancer; Human; Prognosis; Tumor infiltrating lymphocytes

Indexed keywords

INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 10;

BLADDER CANCER; CANCER SURVIVAL; COLON CANCER; DISEASE COURSE; HUMAN; IMMUNOPATHOLOGY; MELANOMA; MICROENVIRONMENT; OVARY CANCER; REVIEW; STATISTICAL SIGNIFICANCE; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL; TUMOR REGRESSION;

EID: 34347340406     PISSN: None     EISSN: 14249634     Source Type: Journal    
DOI: None     Document Type: Review

References (52)

1. Alexandroff AB, Jackson AM, O'Donnell MA, James K. BCG immunotherapy of bladder cancer: 20 years on. Lancet 1999; 353: 1689-1694.
2. Tsuji S, Matsumoto M, Takeuchi O, Akira S, Azuma I, Hayashi A, Toyoshima K, Seya T. Maturation of human dendritic cells by cell wall skeleton of Mycobacterium bovis bacillus Calmette-Guérin: involvement of toll-like receptors. Infect Immun 2000; 68: 6883-6890.
3. de Boer EC, Somogyi L, de Ruiter GJ, de Reijke TM, Kurth KH, Schamhart DH. Role of interleukin-8 in onset of the immune response in intravesical BCG therapy for superficial bladder cancer. Urol Res 1997; 25: 31-34.
4. Thalmann GN, Sermier A, Rentsch C, Möhrle K, Cecchini MG, Studer UE. Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin. J Urol 2000; 164: 2129-2133.
5. Jackson AM, Alexandroff AB, Kelly RW, Skibinska A, Esuvaranathan K, Prescott S, Chisholm GD, James K. Changes in urinary cytokines and soluble intercellular adhesion molecule-1 (ICAM-1) in bladder cancer patients after bacillus Calmette-Guérin (BCG) immunotherapy. Clin Exp Immunol 1995; 99: 369-375.
6. Prescott S, James K, Hargreave TB, Chisholm GD, Smyth JF. Radioimmunoassay detection of interferon-gamma in urine after intravesical Evans BCG therapy. J Urol 1990; 144: 1248-1251.
7. Haaff EO, Catalona WJ, Ratliff TL. Detection of interleukin 2 in the urine of patients with superficial bladder tumors after treatment with intravesical BCG. J Urol 1986; 136: 970-974.
8. De Boer EC, De Jong WH, Steerenberg PA, Aarden LA, Tetteroo E, De Groot ER, Van der Meijden AP, Vegt PD, Debruyne FM, Ruitenberg EJ. Induction of urinary interleukin-1 (IL-1), IL-2, IL-6, and tumour necrosis factor during intravesical immunotherapy with bacillus Calmette-Guérin in superficial bladder cancer. Cancer Immunol Immunother 1992; 34: 306-312.
9. Böhle A, Gerdes J, Ulmer AJ, Hofstetter AG, Flad HD. Effects of local bacillus Calmette-Guerin therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall. J Urol 1990; 144: 53-58.
10. de Boer EC, de Jong WH, van der Meijden AP, Steerenberg PA, Witjes F, Vegt PD, Debruyne FM, Ruitenberg EJ. Leukocytes in the urine after intravesical BCG treatment for superficial bladder cancer. A flow cytofluorometric analysis. Urol Res 1991; 19: 45-50.
11. Coon JS, Weinstein RS, Summers JL. Blood group precursor T-antigen expression in human urinary bladder carcinoma. Am J Clin Pathol 1982; 77: 692-699.
12. Hirohashi S, Clausen H, Yamada T, Shimosato Y, Hakomori S. Blood group A cross-reacting epitope defined by monoclonal antibodies NCC-LU-35 and -81 expressed in cancer of blood group O or B individuals: its identification as Tn antigen. Proc Natl Acad Sci USA 1985; 82: 7039-7043.
13. Korthals HR, Van Vinninghe AL, Neumann HAM. The presence of β 2 microglobulin on the membrane of the keratinocyte in premalignant skin disorders. Br J Dermatol 1981; 104: 515-519.
14. Mauduit G, Turbitt M, MacKie RM. Dissociation of HLA heavy chain and light chain (β2 microglobulin) expression on the cell surface of cutaneous malignancies. Br J Dermatol 1983; 109: 377-381.
15. Nilsson K, Evrin PE, Welsh KI. Production of β2-microglobulin by normal and malignant human cell lines and peripheral lymphocytes. Transplant Rev 1974; 21: 53-84.
16. Turbitt ML, Mackie RM. Loss of β2 microglobulin from the cell surface of cutaneous malignant and premalignant lesions. Br J Dermatol 1981; 104: 507-513.
17. Graham SD. Immunology of the bladder. Urol Clin North Am 1992; 19: 541-548.
18. Hart IR, Birch M, Marshall JF. Cell adhesion receptor expression during melanoma progression and metastasis. Cancer Metastasis Rev 1991; 10: 115-128.
19. Carballido J, Alvarez-Mon M, Solovera OJ, Menéndez-Ondina L, Durántez A. Clinical significance of natural killer activity in patients with transitional cell carcinoma of the bladder. J Urol 1990; 143: 29-33.
20. Dangles V, Validire P, Wertheimer M, Richon S, Bovin C, Zeliszewski D, Vallancien G, Bellet D. Impact of human bladder cancer cell architecture on autologous T-lymphocyte activation. Int J Cancer 2002; 98: 51-56.
21. Haas GP, Solomon D, Rosenberg SA. Tumor infiltrating lymphocytes from nonrenal urological malignancies. Cancer Immunol Immunother 1990; 30: 342-350.
22. Housseau F, Zeliszewski D, Roy M, Paradis V, Richon S, Ricour A, Bougaran J, Prapotnich D, Vallancien G, Benoit G, Desportes L, Bedossa P, Hercend T, Bidart JM, Bellet D. MHC-dependent cytolysis of autologous tumor cells by lymphocytes infiltrating urothelial carcinomas. Int J Cancer 1997; 71: 585-594.
23. Chappell DB, Zaks TZ, Rosenberg SA, Restifo NP. Human melanoma cells do not express Fas (Apo-1/CD95) ligand. Cancer Res 1999; 59: 59-62.
24. Restifo NP. Not so Fas: Re-evaluating the mechanisms of immune privilege and tumor escape. Nat Med 2000; 6: 493-495.
25. Radoja S, Saio M, Frey AB. CD8+ tumor-infiltrating lymphocytes are primed for Fas-mediated activation-induced cell death but are not apoptotic in situ. J Immunol 2001; 166: 6074-6083.
26. Hahne M, Rimoldi D, Schröter M, Romero P, Schreier M, French LE, Schneider P, Bornand T, Fontana A, Lienard D, Cerottini J, Tschopp J. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science 1996; 274: 1363-1366.
27. O'Connell J, O'Sullivan GC, Collins JK, Shanahan F. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 1996; 184: 1075-1082.
28. O'Connell J, Bennett MW, O'Sullivan GC, Collins JK, Shanahan F. The Fas counterattack: cancer as a site of immune privilege. Immunol Today 1999; 20: 46-52.
29. Yagita H, Seino K, Kayagaki N, Okumura K. CD95 ligand in graft rejection. Nature 1996; 379: 682.
30. Chopin D, Barie-Moniri R, Maillé P, Le Frère-Belda M, Muscatelli-Groux B, Merendino N, Lecerf L, Stoppacciaro A, Velotti F. Human urinary bladder transitional cell carcinomas acquire the functional Fas ligand during tumor progression. Am J Pathol 2003; 162: 1139-1149.
31. Nakagomi H, Petersson M, Magnusson I, Juhlin C, Matsuda M, Mellstedt H, Taupin JL, Vivier E, Anderson P, Kiessling R. Decreased expression of the signal-transducing ζ chains in tumor-infiltrating T-cells and NK cells of patients with colorectal carcinoma. Cancer Res 1993; 53: 5610-5612.
32. Mizoguchi H, O'Shea JJ, Longo DL, Loeffler CM, McVicar DW, Ochoa AC. Alterations in signal transducing molecules in T lymphocytes from tumor-bearing mice. Science 1992; 258: 1795-1798.
33. Reichert TE, Strauss L, Wagner EM, Gooding W, Whiteside TL. Signaling abnormalities, apoptosis, and reduced proliferation of circulating and tumor-infiltrating lymphocytes in patients with oral carcinoma. Clin Cancer Res 2002; 8: 3137-3145.
34. Rabinowich H, Banks M, Reichert TE, Logan TF, Kirkwood JM, Whiteside TL. Expression and activity of signaling molecules in T lymphocytes obtained from patients with metastatic melanoma before and after interleukin 2 therapy. Clin Cancer Res 1996; 2: 1263-1274.
35. Lopez CB, Rao TD, Feiner H, Shapiro R, Marks JR, Frey AB. Repression of interleukin-2 mRNA translation in primary human breast carcinoma tumor-infiltrating lymphocytes. Cell Immunol 1998; 190: 141-155.
36. Sheu BC, Lien HC, Ho HN, Lin HH, Chow SN, Huang SC, Hsu SM. Increased expression and activation of gelatinolytic matrix metalloproteinases is associated with the progression and recurrence of human cervical cancer. Cancer Res 2003; 63: 6537-6542.
37. Friberg M, Jennings R, Alsarraj M, Dessureault S, Cantor A, Extermann M, Mellor AL, Munn DH, Antonia SJ. Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection. Int J Cancer 2002; 101: 151-155.
38. Chiou SH, Sheu BC, Chang WC, Huang SC, Hong-Nerng H. Current concepts of tumor-infiltrating lymphocytes in human malignancies. J Reprod Immunol 2005; 67: 35-50.
39. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, Schreiber RD. IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001; 410: 1107-1111.
40. Smyth MJ, Godfrey DI, Trapani JA. A fresh look at tumor immunosurveillance and immunotherapy. Nat Immunol 2001; 2: 293-299.
41. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002; 3: 991-998.
42. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Ann Rev Immunol 2004; 22: 329-360.
43. Deeths MJ, Kedl RM, Mescher MF. CD8+ T cells become nonresponsive (anergic) following activation in the presence of costimulation. J Immunol 1999; 163: 102-110.
44. Sheu BC, Lin RH, Lien HC, Ho HN, Hsu SM, Huang SC. Predominant Th2/Tc2 polarity of tumor-infiltrating lymphocytes in human cervical cancer. J Immunol 2001; 167: 2972-2978.
45. Mostofi FK, Sesterhenn I. Lymphocytic infiltration in relationship to urological tumors. Natl Cancer Inst Monogr 1978; 49: 133-141.
46. Lopez-Beltran A, Morales C, Reymundo C, Toro M. T-zone histiocytes and recurrence of papillary urothelial bladder carcinoma. Urol Int 1989; 44: 205-209.
47. Morita T, Tokue A, Minato N. Analysis of natural killer activity and natural killer cell subsets in patients with bladder cancer. Cancer Immunol Immunother 1990; 32: 191-194.
48. Ikemoto S, Kishimoto T, Wada S, Nishio S, Maekawa M. Clinical studies on cell-mediated immunity in patients with urinary bladder carcinoma: blastogenic response, interleukin-2 production and interferon-gamma production of lymphocytes. Br J Urol 1990; 65: 333-338.
49. Tsujihashi H, Matsuda H, Uejima S, Akiyama T, Kurita T. Immunocompetence of tissue infiltrating lymphocytes in bladder tumors. J Urol 1988; 140: 890-894.
50. Itoh K, Tilden AB, Balch CM. Interleukin 2 activation of cytotoxic T-lymphocytes infiltrating into human metastatic melanomas. Cancer Res 1986; 46: 3011-3017.
51. Lipponen PK, Eskelinen MJ, Jauhiainen K, Harju E, Terho R. Tumour infiltrating lymphocytes as an independent prognostic factor in transitional cell bladder cancer. Eur J Cancer 1993; 29: 69-75.
52. Sharma P, Shen Y, Wen S, Yamada S, Jungbluth AA, Gnjatic S, Bajorin DF, Reuter VE, Herr H, Old LJ, Sato E. CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. Proc Natl Acad Sci U S A 2007; 104: 3967-3972.